CN103720810A - Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine - Google Patents
Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine Download PDFInfo
- Publication number
- CN103720810A CN103720810A CN201210391588.9A CN201210391588A CN103720810A CN 103720810 A CN103720810 A CN 103720810A CN 201210391588 A CN201210391588 A CN 201210391588A CN 103720810 A CN103720810 A CN 103720810A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- parts
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of the disease, and a preparation method of the medicine. The medicine is used for treating diseases such as chest distress, angina, hypertension, dizziness, headache, neck pain, arrhythmia and hyperlipidemia caused by qi-stagnation and blood stasis coronary heart disease. The medicine is prepared from hawthorn, the root of red-rooted salvia, pachyrhizua angulatus, pseudo-ginseng and elecampane, and the preparation method comprises the following steps: weighing the pseudo-ginseng and the elecampane according to a ratio, crushing, performing reflux extraction on the hawthorn and the pachyrhizua angulatus, boiling in water, filtering, combining the medicine liquid, concentrating, uniformly mixing, drying to obtain a main medicine extract, and uniformly mixing with auxiliary materials to prepare sustained-release pellets or concentrated pellets. Clinical experiment shows that the medicine can be smoothly and continuously released, so that the bioavailability is improved, and the toxic and side effects and due to sustained releasing of the medicine, irritation on human bodies can be well alleviated.
Description
Technical field
The present invention relates to the preparation method of a kind of Chinese medicine and medicine thereof, relate to specifically a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof and preparation method thereof.
Background technology
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, or claims ischemic heart desease, is that middle-aged and elderly people is the most common and endanger one of maximum cardiovascular and cerebrovascular disease.Its main clinical manifestation is that pain or squeezing sense often occur in pareordia, and pain can be takeed on left or left upper extremity front inner side radiation, how with symptoms such as pale complexion, chest distress, dyspnea, generally lasts 1～5 minute.Often because of tired, excited, catch cold, the factor such as heavy meal, smoking brings out.According to the degree of coronary atherosclerosis and clinical manifestation, clinical five types of latent coronary heart disease, angina pectoris, myocardial infarction, arrhythmia and the heart failure that are divided into.
Coronary heart disease belongs to the category of the diseases such as the traditional Chinese medical science " thoracic obstruction ", " angina pectoris ", " precordial pain with cold limbs ", " cardiopalmus ".The traditional Chinese medical science thinks that the generation of primary disease is how relevant with the factor such as inward invasion of pathogenic cold, improper diet, disorder of emotion, aged debility.Stage of attack, should be rescued in time, and the catabasis can take the circumstances into consideration to select dietetic therapy to take good care of, to reduce outbreak.Clinical syndrome differentiation is mainly divided into the disease types such as QI stagnated by cold, expectorant stasis of blood impatency, deficiency of both QI and YIN, qi depression to blood stasis, insufficiency of vital energy and blood.
Qi stagnation and blood stasis type: clinical manifestation is suffocating pain over the chest, twinge, localized pain, vexed uneasiness.Or time had palpitation not peaceful, two the side of body distensions, happiness sigh.Purplish tongue, thready and hesitant pulse or knot generation.Myocardial ischemia refers to that the hemoperfusion of heart reduces, and causes the oxygen supply of heart to reduce, and energy metabolism of myocardial is undesired, can not support a kind of pathological state of the normal work of heart.The blood supply of heart is not unalterable, but exists all the time fluctuation, but this fluctuation is through body self-regulation, impels blood supply and demand relatively constant, and assurance heart is normally worked.If any reason causes myocardial ischemia, through body, regulate and can not meet heart working needs, this has just formed myocardial ischemia truly.
Clinical demonstration: causing main, the modal cause of disease of myocardial ischemia, is coronary stricture.And the main cause of coronary stricture is atherosclerosis.The heart disease causing because of coronary atherosclerosis is exactly the coronary heart disease that the large daily life of a family is said.So coronary heart disease is myocardial ischemia " arch-criminal ".
Myocardial ischemia all may bring many adverse effects to heart and whole body.Oxygen is the movable requisite material of myocardial cell, and oxygen by blood transport to cell.Heart does not have " oxygen warehouse ", relies on myocardial blood flow completely, so once ischemia can cause anoxia at once.The direct result of anoxia is that myocardial cell aerobic metabolism weakens, and production capacity reduces, and essential energy supply deficiency while making cardiomotility causes that angina pectoris, arrhythmia, cardiac function decline.Meanwhile, the refuse of metabolism can not be removed effectively in time, easily has a negative impact.Ischemia, anoxia, lack energy, finally can affect the contractile function of heart.If have 20%～25% cardiac muscle to stop shrinking, conventionally there will be left chamber function exhaustion; If have more than 40% cardiac muscle not shrink, just have the exhaustion of severe cardiac pump function.If this situation occurs suddenly, just there will be breakneck cardiogenic shock.Acute myocardial infarction is just normal relevant to this situation.
Myocardial ischemia also can damage diastolic function.Shrink bad and diastole is bad combines, easily cause ventricular filling pressure to raise, cause pulmonary congestion, also can cause that complicated substance metabolism is disorderly and myocardial electrical activity is not normal.Therefore, once there is myocardial ischemia, should find cause of disease symptomatic treatment accurately, just can avoid potential serious consequence.
So-called silent ischemia refers to that diagnosis of coronary heart disease determined the objective indicator of myocardial ischemia, and as the variation of electrocardiogram typical case ischemic ST etc., it is a kind of specific type of coronary heart disease.But often by people, ignored due to asymptomatic.
Silent ischemia comes into one's own just day by day, is mainly because a large amount of in recent years research is found, in about 25%～50% acute Sudden Death, before death without angina pectoris history of attack; But in nearly 90% postmortem, find that these have serious coronary atherosclerosis per capita.The U.S. approximately 2%～4% is the asymptomatic middle age of health seemingly, checks and finds that there is obvious Coronary Artery Lesions and silent ischemia outbreak.The normally fatal arrhythmia of reason of sudden death, and before the quick ventricular arrhythmia outbreak of mortality, electrocardiogram can detect between silent ischemia and sudden death may cause effect relation.In addition, someone reports, the U.S. has 450,000 people's sudden deaths every year, wherein 20%～50% dies from bradyarrhythmia, before this or simultaneously, and often with silent ischemia.Also have people to carry out finding in follow-up observation in 30 years to 5209 routine patients with coronary artery diseases, 25% myocardial infarction is asymptomatic, and in its 10 years, mortality rate is 84%.Result shows, the sudden death rate of asymptomatic myocardial infarction is similar with case fatality rate to the sudden death rate of Symptomatic myocardial infarction with case fatality rate.Even occurring in the patient of acute myocardial infarction, also still have 30% patient there is no symptom, this show infarction around cardiac muscle have remaining ischemia, this remaining ischemia often causes again myocardial infarction and sudden death.Medically silent ischemia is divided at present to following three types:
I type, safe silent myocardial ischemia: this kind of is asymptomatic, be to be accidentally found to have myocardial ischemia, and someone estimates that (population) accounts for 2%～5% in the complete middle-aged male without coronary heart disease symptom.
Silent ischemia after II type, myocardial infarction: though truly have the myocardial ischemia person of existence comparatively common without angina pectoris after myocardial infarction.This kind of patient's prognosis is more bad compared with I type, and especially, when left ventricular function is abnormal, its mortality rate is 5%～6%.
III type, angina pectoris are with silent ischemia: research shows in patient with angina pectoris that 70%～80% exists silent ischemia simultaneously, and can occur in dissimilar angina pectoris.Must be pointed out, functions in patients with unstable angina often can cause fatefulue arrhythmia with silent ischemia, through treatment after transference cure but still have myocardial ischemia exist, this is the important indicator of prognosis mala.
Therefore, silent myocardial ischemia should cause people's enough attention.It can affect the prognosis of various coronary heart disease, so positive Clinics and Practices.
Therefore, develop a kind of toxic and side effects little, convenient oral, the Chinese medicine novel form that bioavailability is high.The medicine of the diseases such as uncomfortable in chest, the angina pectoris, hypertension, dizziness, headache, neck pain and the arrhythmia that cause for qi stagnation and blood stasis type coronary heart disease, hyperlipidemia is very urgent, very important.
Summary of the invention
The object of this invention is to provide a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof and preparation method thereof, this medicine can be treated blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain significantly, stably, the effect of the disease such as uncomfortable in chest, the angina pectoris, hypertension, dizziness, headache, neck pain and the arrhythmia that have that good treatment qi stagnation and blood stasis type coronary heart disease causes, hyperlipidemia.
The object of the present invention is achieved like this, pharmaceutical composition provided by the present invention, and its active component is made by the raw material of following mass parts: 15～20 parts of Fructus Crataegis, 15～20 parts of Radix Salviae Miltiorrhizaes, 15～20 parts of Radix Puerariaes, 1～2 part of Radix Notoginseng, 1～2 part of the Radix Aucklandiae.
The preferred mass parts of above-mentioned each raw material is: 17～19 parts of Fructus Crataegis, 17～19 parts of Radix Salviae Miltiorrhizaes, 17～19 parts of Radix Puerariaes, 1～1.5 part of Radix Notoginseng, 1～1.5 part of the Radix Aucklandiae.
Most preferred mass parts is: 18. 75 parts of Fructus Crataegis, 18. 75 parts of Radix Salviae Miltiorrhizaes, 18. 75 parts of Radix Puerariaes, 1. 25 parts of Radix Notoginseng, 1. 25 parts of the Radix Aucklandiae.
Preparation pharmaceutical composition of the present invention each raw material according to parts by weight as proportioning processing, in actual process of manufacture, can increase or reduce according to above-mentioned corresponding proportion, if large-scale processing can with kilogram or with tonnage unit, but the weight proportion ratio of each crude drug remains unchanged.
The preparation method of pharmaceutical composition of the present invention comprises the following steps:
1. the preparation method of, making slow-release micro-pill is: by the five tastes in the crude drug of said ratio, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder A; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste B that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste C that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick paste B be dry, pulverize into fine powder and Radix Notoginseng with C at 60 ℃～120 ℃, Radix Aucklandiae fine powder A mixes, and makes micropill, bag slow release film-coat, obtains.
2., the preparation method of making concentrated pill is: get the five tastes in recipe quantity, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder A; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste B that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste C that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick paste B be dry, pulverize into fine powder and Radix Notoginseng with C at 60 ℃～120 ℃, Radix Aucklandiae fine powder A mixes, general ball, obtains.
In described said medicine, can add one or more pharmaceutically acceptable carriers, described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier and the lubricant etc. of pharmaceutical field routine.
Utilize pharmaceutical composition of the present invention can also make tablet, dispersible tablet, hard capsule, soft capsule, powder, oral liquid etc., the medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.
The consumption of described slow-release micro-pill medicine, 0.19g*80 ball/bottle; Instructions of taking: every day 1 time, each 8 balls.
The consumption of described concentrated pill medicine, 0.19g*80 ball/bag; Instructions of taking: every day 3 times, each 8 balls.
Medicine of the present invention has the following advantages and good effect:
1, Fructus Crataegi in the present invention: energy prevention and cure of cardiovascular disease, has blood vessel dilating, heart tonifying, increase coronary flow, improves heart vigor, stimulating central nervous system system, reduces blood pressure and cholesterol, vessel softening and diuresis and sedation; Prevent and treat arteriosclerosis, anti-aging, anticancer effect.Crataegolic acid also has cardiotonic, also helpful to senile heart disease.
Radix Salviae Miltiorrhizae: promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.
Pachyrhizua angulatus: fever caused by exogenous pathogens, rigidity pain on the head and nape, measles from the beginning of, rash go out smooth, epidemic febrile disease is thirsty, quench one's thirst, have loose bowels, dysentery, hypertension, coronary heart disease.
Radix Notoginseng: hemostasis; Loose blood; Analgesic therapy.Be used for falling and flutter congestive edema, thoracic obstruction angor, lump in the abdomen; Blood stasis amenorrhea; Dysmenorrhea; The cloudy stomachache of the stasis of blood in puerperal; Sore, carbuncle and painful swelling.
The Radix Aucklandiae: promoting the circulation of QI to relieve pain; Intestinal stasis relieving in tune.For born of the same parents, coerce distension foot; Abdominal distention; Tell and have loose bowels; Heavy after dysentery.
Above drug synergism, has the effect of blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain.The diseases such as uncomfortable in chest, the angina pectoris, hypertension, dizziness, headache, neck pain and the arrhythmia that are used for the treatment of that qi stagnation and blood stasis type coronary heart disease causes, hyperlipidemia.
2, sustained-release pellet preparation in the present invention, can be steady, lasting release medicine, and when improving bioavailability, slowly release more can alleviate toxic and side effects and the zest to human body.
3, concentrated pill in the present invention, facilitates all kinds of crowds to use.Can significantly strengthen its rate of release, when reaching quick acting, reduce gastrointestinal irritation, there are blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain.The diseases such as uncomfortable in chest, the angina pectoris, hypertension, dizziness, headache, neck pain and the arrhythmia that are used for the treatment of that qi stagnation and blood stasis type coronary heart disease causes, hyperlipidemia.
The medicament slow release micropill of the diseases such as that 4, the present invention is used for the treatment of that qi stagnation and blood stasis type coronary heart disease causes is uncomfortable in chest, angina pectoris, hypertension, dizziness, headache, neck pain and arrhythmia, hyperlipidemia is effectively for the continuing of qi stagnation and blood stasis type coronary heart disease, stable treatment, its preparation technology is simple, for raising Chinese Herbs, raising bioavailability, release, stablize, promote new drug development and promote the modernization of Chinese medicine to there is immeasurable effect, have good scientific research and application prospect, this will produce significant impact to the Chinese medicine research of China and exploitation.
5, the conventional formulation-pill of a kind of medicine for the treatment of qi stagnation and blood stasis type coronary heart disease of the present invention, for qi stagnation and blood stasis type coronary heart disease, be difficult for making the quick releasing formulation that rate of release is fast, gastrointestinal irritation is larger, therefore the present invention is made as common formulations pill, can reach rapid-action, the object that GI irritation is little.
clinical data
1., case selection: the patient who accepts for medical treatment is divided into two groups at random, treatment group: 40 examples, wherein male 24 examples, female's 16 examples.Age between 35-78 year, course of disease 1-20.Matched group: 20 examples, male 12 examples, female's 8 examples.Between age 37-75 year, course of disease 2-19.Two groups of patients learn by statistics to process in age, sex, the course of disease and are P > 0.05, without significant difference, have comparability.
2., medication standard: a kind of oral drugs for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof, month is a course for the treatment of, takes three courses for the treatment of and is advisable.
3., clinical case
Case 1 patient Wang, man, 42 years old.Before 2 years, felt chest pain, stuffy, do electrocardiographic examination and be considered as coronary heart disease.Within nearly 20 days, pain is shown in heavily, and outbreak in a day more than ten times continues 5-10 minute at every turn, breathes hard, and tired, complexion is gloomy.Take 15 days, symptom uncomfortable in chest slows down to some extent, and electrocardiogram shows normal.
Case 2 patient Lee, female, 65 years old.In the obvious inducement of more than ten Nian Qianwu, occurring chest pain, is precordial fullness pain, and without feeling sick, vomiting etc., continuing 5 minutes just can spontaneous remission, is paid attention to.Between more than ten years, above-mentioned symptom constantly shows effect around here, but does not accept regular treatment.Before one month, due to excited, hypertension, is up to 180/100mmHg, and the logical paresthesia epilepsy of precordial fullness is frequent, is hospitalized for treatment.Take medicine one month, symptom uncomfortable in chest disappears substantially, and it is normal that electrocardiogram recovers.
Case 3 patient Zhao, man, 63 years old, nearly 10 years of hypertension, nearly 3 years pained 3-5 minute as lasting in cutter strand,, perspiration, weak swollen with breast.Be diagnosed as coronary heart disease.The typical angina pectoris of Zhao Qiangyou, each outbreak is all relevant with emotion, belongs to the clinical modal symptom of Coronary Heart Disease Patients.After drug administration 2 months, blood pressure recovers normally substantially, and chest pain, breast is swollen, and symptom is alleviated to some extent.
Case 4 patient Tang, man 37 years old, before 3 years, after body-building, felt suddenly breastbone have an intense pain, uncomfortable in chest, breathe hard, and then dripping sweat, after several hours symptom just gradually alleviate.Do not take notice of at that time, do not recognize it is the symptom of heart infarction.Half a year up to date, when activity, often feel pareordia twinge and with back pain, hospitalized to have a thorough examination, be diagnosed as coronary heart disease, unstable angina pectoris.Take medicine after three months, above-mentioned symptom disappears, and Electrocardioscopy is normal.
The case 5 patient Qin, female, 68 years old, the retirement professor of university, coronary heart disease for many years, is leaned on SUXIAO JIUXIN WAN always, the medicines such as nitroglycerin maintain, repeatedly outbreak every year, emergency treatment is hospitalized for treatment, and still by medicine, maintains subsequently, electrocardiogram presents the low flat change of ST section, its son is Medical College Graduate, often posts foreign new drugs, but take the rear state of an illness, still loses alleviation.Take medicine three months, seizure frequency reduces, and when outbreak symptom relax to some extent.
4., the criterion of therapeutic effect:
Effective judgement: angina pectoris symptom disappears substantially and/or ST section declines recovers normally or roughly normal; The above person of cardiac function progress secondary is effective;
Good effect is judged: angina pectoris symptom alleviates, extend interval time and/or ST section decline go up 0.05 millivolt above but do not recover normal person; Cardiac function progress one-level person is good effect;
Invalid judgement: angina pectoris symptom is not improved or increases the weight of and/or ECG ST section gos up not reach above-mentioned standard person; Cardiac function and blood pressure are unchanged is invalid.
5., the statistics of therapeutic effect:
6., conclusion: from upper table, treatment group 40 examples, effective 25 examples, good effect 14 examples, invalid 1 example, total effective rate 97.5%.Matched group 20 examples, effective 4 examples, good effect 12 examples, invalid 4 examples, total effective rate 80.0%.Two groups of comparisons, P < 0.05, illustrates that between two groups, curative effect comparing difference has significance.
The specific embodiment
Embodiment 1
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Slow-release micro-pill processed: the five tastes in formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae, Radix Salviae Miltiorrhizae were soaked after 1 hour, and heating decocts three times, 2 hours for the first time, second and third time is 1 hour, amount of water is medical material 8 times, collecting decoction, filter, the filtrate thick paste 180g that relative density is 1.30 when being concentrated at 20 ℃ for 70 ℃, mixes with Radix Notoginseng, Radix Aucklandiae fine powder, then adds microcrystalline Cellulose 20g and mix, adding purified water constantly mediates, make concentrated micropill 200g, bag slow release film-coat, obtains.
Embodiment 2
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Slow-release micro-pill processed: the five tastes in formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae added 75%～90% soak with ethanol after 40 minutes, and heating and refluxing extraction twice, is 2 hours, the amount that at every turn adds ethanol is medical material 6 times, merge alcohol extract, decompression recycling ethanol, the thick paste that while being concentrated into 20 ℃, relative density is 1.30; Radix Salviae Miltiorrhizae decocts with water twice, be 2 hours, each amount of water is medical material 8 times, collecting decoction, filter, filtrate concentrates, dry, pulverize into fine powder (153.5g) and Radix Notoginseng, Radix Aucklandiae fine powder and mixes in the time of 70 ℃, then adds microcrystalline Cellulose 11.5g and mix, adding purified water constantly mediates, make concentrated micropill 190g, bag slow release film-coat, obtains.
Embodiment 3
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Slow-release micro-pill processed: the five tastes in formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick pastes be dry, pulverize into fine powder at 60 ℃～120 ℃ and Radix Notoginseng, Radix Aucklandiae fine powder mix, make 12～20 order micropill 190g, bag slow release film-coat, obtains
Embodiment 4
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Concentrated pill processed: get the five tastes in recipe quantity formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae, Radix Salviae Miltiorrhizae were soaked after 1 hour, heating decocts three times, and 2 hours for the first time, second and third time was 1 hour, amount of water is 8 times of medical material, collecting decoction, filters the thick paste 179.5g that filtrate relative density when being concentrated into 20 ℃ for 70 ℃ is 1.30, mix with Radix Notoginseng, Radix Aucklandiae fine powder, add again starch 10g to mix, the concentrated micropill 190g(1000 ball of system), obtain.
Embodiment 5
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Concentrated pill processed: get the five tastes in recipe quantity formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae added 75%～90% soak with ethanol after 40 minutes, and heating and refluxing extraction twice, is 2 hours, the amount that at every turn adds ethanol is medical material 6 times, merge alcohol extract, decompression recycling ethanol, the thick paste that while being concentrated into 20 ℃, relative density is 1.30; Radix Salviae Miltiorrhizae decocts with water twice, be 2 hours, each amount of water is medical material 8 times, collecting decoction, filters, filtrate is concentrated in the time of 70 ℃, dry, be broken into fine powder (154g) and Radix Notoginseng, Radix Aucklandiae fine powder and mix, then add starch 11g and mix, add purified water and constantly mediate, make concentrated micropill 190g(1000 ball), obtain.
Embodiment 6
In prescription ratio weighting raw materials Fructus Crataegi 187.5g, Radix Salviae Miltiorrhizae 187.5g, Radix Puerariae 187.5g, Radix Notoginseng 12.5g, Radix Aucklandiae 12.5g.
Concentrated pill processed: get the five tastes in recipe quantity formula, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste 180.5g that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick pastes be dry, pulverize into fine powder at 60 ℃～120 ℃ and Radix Notoginseng, Radix Aucklandiae fine powder mix, general ball, obtains 1000 balls.
Micropill unit's formula adjuvant is microcrystalline Cellulose 0～20g; Concentrated pill unit's formula adjuvant is starch 0～20g.
Claims (7)
1. a medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof, is characterized in that: this active constituents of medicine is made by the raw material of following mass parts: 15～20 parts of Fructus Crataegis, 15～20 parts of Radix Salviae Miltiorrhizaes, 15～20 parts of Radix Puerariaes, 1～2 part of Radix Notoginseng, 1～2 part of the Radix Aucklandiae.
2. a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof according to claim 1, is characterized in that: described active component is made by the raw material of following weight parts: 17～19 parts of Fructus Crataegis, 17～19 parts of Radix Salviae Miltiorrhizaes, 17～19 parts of Radix Puerariaes, 1～1.5 part of Radix Notoginseng, 1～1.5 part of the Radix Aucklandiae.
3. a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof according to claim 1, is characterized in that: described active component is made by the raw material of following weight parts: 18. 75 parts of Fructus Crataegis, 18. 75 parts of Radix Salviae Miltiorrhizaes, 18. 75 parts of Radix Puerariaes, 1. 25 parts of Radix Notoginseng, 1. 25 parts of the Radix Aucklandiae.
4. according to a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof described in claim 1 or 2 or 3, it is characterized in that: described complication be following at least one: uncomfortable in chest, angina pectoris, hypertension, dizziness, headache, neck pain and arrhythmia and hyperlipidemia.
5. a kind of medicine that is used for the treatment of qi stagnation and blood stasis type coronary heart disease and complication thereof according to claim 1, is characterized in that: the dosage form of described medicine is oral administration pills, and described oral administration pills is slow-release micro-pill and concentrated pill.
6. a preparation method for medicine as claimed in claim 1, is characterized in that: comprise the following steps: by the five tastes in the crude drug of said ratio, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder A; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste B that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste C that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick paste B be dry, pulverize into fine powder and Radix Notoginseng with C at 60 ℃～120 ℃, Radix Aucklandiae fine powder A mixes, and makes micropill, bag slow release film-coat, obtains.
7. a preparation method for medicine as claimed in claim 1, is characterized in that: comprise the following steps: get the five tastes in recipe quantity, get Radix Notoginseng, Radix Aucklandiae powder is broken into fine powder A; Fructus Crataegi, Radix Puerariae added 50%～95% ethanol warm macerating after 30 minutes, heating and refluxing extraction secondary, 2.5 hours for the first time, 1.5 hours for the second time, the addition of each 50%～95% ethanol is 6 times of medical material, merge alcohol extract, decompression recycling ethanol, the thick paste B that while being concentrated into 20 ℃, relative density is 1.30～1.35; Radix Salviae Miltiorrhizae decocts with water secondary, 2 hours for the first time, 1.5 hours for the second time, each amount of water is medical material 8 times, collecting decoction, filters the thick paste C that when filtrate is concentrated into 20 ℃, relative density is 1.30～1.35; Above-mentioned two kinds of thick paste B be dry, pulverize into fine powder and Radix Notoginseng with C at 60 ℃～120 ℃, Radix Aucklandiae fine powder A mixes, and makes concentrated pill, obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210391588.9A CN103720810A (en) | 2012-10-16 | 2012-10-16 | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210391588.9A CN103720810A (en) | 2012-10-16 | 2012-10-16 | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103720810A true CN103720810A (en) | 2014-04-16 |
Family
ID=50445272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210391588.9A Pending CN103720810A (en) | 2012-10-16 | 2012-10-16 | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103720810A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689241A (en) * | 2015-03-18 | 2015-06-10 | 付连进 | Medicine for treating Qi-stagnation and blood stasis type coronary heart disease and preparation method thereof |
| CN108815255A (en) * | 2018-08-07 | 2018-11-16 | 家胜男 | A kind of Chinese medicine of assistance of acupuncture treatment hypertension |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362193A (en) * | 2001-01-02 | 2002-08-07 | 杨孟君 | Namo xinkeshu medicine and its preparation |
| KR20050026636A (en) * | 2003-09-09 | 2005-03-15 | 문조웅 | Mediicinal herbs composition for preventing and treating essential hypertension |
| CN1616060A (en) * | 2004-10-10 | 2005-05-18 | 山东沃华医药科技股份有限公司 | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain |
| CN1714836A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Use of medicine in preparing medicine for treating anti-aspirin |
| CN1733109A (en) * | 2005-08-11 | 2006-02-15 | 贵阳利多药物技术开发有限公司 | Soft capsule for treating coronary disease and process for preparing the same |
| CN1839955A (en) * | 2006-01-23 | 2006-10-04 | 重庆希尔安药业有限公司 | Capsule for protecting heart and its preparing process |
| CN1883587A (en) * | 2006-05-19 | 2006-12-27 | 山东沃华医药科技股份有限公司 | Preparation of 'Xin Ke Shu' tablet for treating coronary heart disease |
| CN101036707A (en) * | 2006-03-13 | 2007-09-19 | 北京奇源益德药物研究所 | Pill for easing heart and the method for preparing the same |
-
2012
- 2012-10-16 CN CN201210391588.9A patent/CN103720810A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362193A (en) * | 2001-01-02 | 2002-08-07 | 杨孟君 | Namo xinkeshu medicine and its preparation |
| KR20050026636A (en) * | 2003-09-09 | 2005-03-15 | 문조웅 | Mediicinal herbs composition for preventing and treating essential hypertension |
| CN1714836A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Use of medicine in preparing medicine for treating anti-aspirin |
| CN1616060A (en) * | 2004-10-10 | 2005-05-18 | 山东沃华医药科技股份有限公司 | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain |
| CN1733109A (en) * | 2005-08-11 | 2006-02-15 | 贵阳利多药物技术开发有限公司 | Soft capsule for treating coronary disease and process for preparing the same |
| CN1839955A (en) * | 2006-01-23 | 2006-10-04 | 重庆希尔安药业有限公司 | Capsule for protecting heart and its preparing process |
| CN101036707A (en) * | 2006-03-13 | 2007-09-19 | 北京奇源益德药物研究所 | Pill for easing heart and the method for preparing the same |
| CN1883587A (en) * | 2006-05-19 | 2006-12-27 | 山东沃华医药科技股份有限公司 | Preparation of 'Xin Ke Shu' tablet for treating coronary heart disease |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689241A (en) * | 2015-03-18 | 2015-06-10 | 付连进 | Medicine for treating Qi-stagnation and blood stasis type coronary heart disease and preparation method thereof |
| CN108815255A (en) * | 2018-08-07 | 2018-11-16 | 家胜男 | A kind of Chinese medicine of assistance of acupuncture treatment hypertension |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393749A (en) | Traditional Chinese medicine for preventing and treating ischemic cardiovascular and cerebrovascular diseases | |
| CN103720810A (en) | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine | |
| CN102626510B (en) | Traditional Chinese medicine composite for treating diabetic cardiopathy and preparation method and applications thereof | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN100574800C (en) | A kind of Chinese patent medicine for the treatment of atherosclerosis of cardio-cerebral arteria and preparation method thereof | |
| CN102302550A (en) | Medicament for treating coronary heart disease | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN101066391B (en) | Medicine composition for treating hypertension | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN102961540A (en) | Medicine for treating coronary heart disease and preparation method for same | |
| CN103385963A (en) | Chinese medicine preparation for treating angina pectoris caused by coronary heart disease | |
| CN107582866A (en) | Dendrobium candidum and Amlodipine are preparing the application process in treating hypertension drug | |
| CN101347494A (en) | Health products for preventing and treating women's climacteric syndrome | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN101991647A (en) | Traditional Chinese medicine for treating diabetic coronary heart diseases | |
| CN104042779B (en) | A kind of Chinese medicine composition and preparation method containing tea polyphenols | |
| CN103655917B (en) | A kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease | |
| CN102091229A (en) | Traditional Chinese medicine for treating diabetic coronary heart disease | |
| CN103463575B (en) | Traditional Chinese medicine for treating heart-spleen-deficiency type arrhythmia and preparation method thereof | |
| CN101991648A (en) | Traditional Chinese medicine for treating diabetic coronary heart disease | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN102836320A (en) | Chinese medicinal pill for treating tachyarrhythmia | |
| CN103800428A (en) | Medicine for treating yin deficiency and yang excess syndrome of hypertension and coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140416 |